Document is current
Any future updates will be listed below
-
Authors
Tsukahara, Shigehiro
Shiota, Masaki
Matsumoto, Takashi
Takamatsu, Dai
Nagakawa, Shohei
Noda, Nozomi
Matsumoto, Shinya
Yagi, Mikako
Uchiumi, Takeshi
Kunisaki, Yuya
Kang, Dongchon
Eto, Masatoshi
- License Information
-
More Information
Article History
Received: 9 December 2024
Revised: 11 March 2025
Accepted: 3 April 2025
First Online: 24 April 2025
Competing interests
: Masaki Shiota received honoraria from Janssen Pharmaceuticals, AstraZeneca, Astellas Pharma, Sanofi, and Bayer Yakuhin, as well as research funding support from Astellas Pharma. Masatoshi Eto received honoraria from Ono Pharmaceutical, Takeda Pharmaceuticals, Novartis Pharma, Pfizer, Bristol-Myers Squibb, Janssen Pharmaceuticals, MSD, Merck Biopharma, AstraZeneca, and Eisai, as well as research funding support from Bayer Yakuhin, Astellas Pharma, Ono Pharmaceutical, and Takeda Pharmaceuticals. Masaki Shiota is an Associate Editor at BJC Reports. He was not involved in any aspect of handling of this manuscript or any editorial decisions.
: Written informed consent was obtained from all patients. The study was approved by Kyusyu University Hospital Institutional Review Board (approval number 2022-157). The study was conducted in accordance with the principles described in the Declaration of Helsinki and the Ethical Guidelines for Epidemiological Research enacted by the Japanese Government.
